Preliminary Statement of Results for the year ended 31 December 2024 Irish Continental Group (ICG), the leading Irish-based maritime transport group, reports its financial performance for the year ended 31 December 2024. HighlightsFinancial Summary          2024 2023 Change  Revenue   €603.8m €572.0m +5.6%  EBITDA   €133.5m €132.6m +0.7%  Operating profit   €69.1m €68.4m +1.0%  Basic earnings per share   36.3c 36.2c ...

EXOSENS DELIVERS VERY STRONG FULL-YEAR 2024 RESULTS, OVERPERFORMING ON ITS IPO GUIDANCE SUSTAINED GROWTH DYNAMIC ANTICIPATED FOR 2025-2026 FY 2024 HIGHLIGHTSStrong revenue growth of +35.0%, above IPO guidance, to €394.1m in 2024, reflecting dynamic like-for-like growth (+24.9%) and successful integration of bolt-on acquisitions Significant increase in profitability, with adjusted EBITDA of €118.5m in 2024 (+37.8%), representing a best-in-class margin of 30.1% (vs. 29.5% in 2023), above IPO guidance and above top range of estimated landing given in January 2025 Net profit of €30.7m in 2024, recording a strong growth of +66.7% over 2023 Robust balance sheet with a net leverage of 1.2x at year-end 2024, enabling the execution of our growth strategy Proposed payment of a €0.10 cash dividend per share for the 2024 fiscal year, for the first...

BALTIMORE, Feb. 28, 2025 (GLOBE NEWSWIRE) — MarketWise, Inc. (NASDAQ: MKTW) (“MarketWise” or the “Company”), a leading multi-brand digital subscription services platform that provides premium financial research, software, education, and tools for self-directed investors, today reported financial results for fourth quarter 2024.(1) Fourth Quarter 2024 Highlights(1)(2)Paid Subscribers were 506 thousand as of December 31, 2024 compared with 737 thousand as of December 31, 2023 Total Net Revenue was $97.5 million in 4Q 2024 compared with $112.2 million in 4Q 2023 Total Billings was $55.4 million in 4Q 2024 compared with $93.6 million in 4Q 2023 Net Income was $26.4 million in 4Q 2024 compared with $1.9 million in 4Q 2023 Cash from Operating Activities of $6.0 million in 4Q 2024 compared with $17.5 million in 4Q 2023 Cash and Cash...

MONTRÉAL, Feb. 28, 2025 (GLOBE NEWSWIRE) — Premier Health of America Inc. (TSXV: PHA) (the “Corporation”), a leading Canadian Healthtech company, announces it has filed its unaudited Quarterly Consolidated Financial Statements and MD&A for its first quarter ended on December 31st, 2024.     Highlights     (in thousands of Canadian dollars) Dec. 30, 2024(3 months) Dec. 30, 2023(3 months)Revenues 32,132   36,973  Gross margin (1) 5,137   7,657  Gross margin as a % of revenues 16.0 % 20.1 %Adjusted EBITDA (1) 705   2,622  Net Loss (2,261 ) (231 )(1)  See the Corporation’s MD&A for details on these non-GAAP measures.   SummaryAdjusted EBITDA for the quarter was $0.7M ($2.6M for the same period in 2023), mainly driven by a decline in the Quebec market. Net Loss for the quarter was $2.3M...

Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populations and continued favorable tolerability      Announced positive interim 32-week data for 4D-150 in DME from Part 1 of SPECTRA clinical trial and alignment with FDA for a single Phase 3 trial being acceptable for the basis of BLA submission for 4D-150 in DME when combined with data generated from 4FRONT Phase 3 trials in wet AMD 4FRONT Phase 3 program in wet AMD on track with initiation of 4FRONT-1 expected in March 2025 and 4FRONT-2 in Q3 2025, with topline data from both studies expected in 2H 2027 Strategically focused pipeline to optimize resource allocation and extend cash runway to advance product candidates with strongest clinical proof...

Wa’el HashadWa’el Hashad, Chief Executive Officer, Longeveron Inc.Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more than 90% enrollment and is expected to complete enrollment in the second quarter of 2025 Lomecel-B™ Biological License Application (BLA) submission for full traditional approval anticipated in 2026, if ELPIS II is successful FDA meeting anticipated late in first quarter of 2025 to discuss possible development paths for Lomecel-B™ in mild Alzheimer’s disease WHO International Nonproprietary Names (INN) Expert Committee approved “laromestrocel” for the non-proprietary name of Lomecel-B™ Total Revenue for 2024 increased 237% year-over-year...

Net income on an adjusted basis increased 9% in the fourth quarter and 23% for the year SHELTON, Conn., Feb. 28, 2025 (GLOBE NEWSWIRE) — Acme United Corporation (NYSE American: ACU) today announced that net sales for the quarter ended December 31, 2024 were $45.9 million compared to $41.9 million in the fourth quarter of 2023, an increase of 10%. Net sales for the year ended December 31, 2024 were $194.5 million compared to $191.5 million in 2023, an increase of 2%. Excluding the impact of the sale of the Camillus and Cuda hunting and fishing product lines on November 1, 2023, net sales for 2024 increased 6% compared to 2023. Net income for the quarter ended December 31, 2024 was $1.70 million, or $0.41 per diluted share, compared to $1.56 million, or $0.40 per diluted share (as adjusted) for the same period in 2023 an increase...

BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided an update on the interim analysis for Study 1 of the Essential3 program of ulixacaltamide in essential tremor (ET), an update on other therapies in development and a financial update. Results of the Planned Interim Analysis and Update on Topline Read-out for the Essential3 Program: The Independent Data Monitoring Committee (IDMC) overseeing the interim analysis of Study 1 of the Essential3 program has provided Praxis with the outcome of such analysis. Based on the predefined decision framework for Study 1, the IDMC has recommended...

Revenue of $65.4 million for Q4 2024 and $254.6 million for FY 2024 Q4 2024 Commerce Media Solutions revenue grew 139% to $17.2 million (26% of consolidated revenue) from $7.2 million (10% of revenue) in Q4 2023 with gross profit margin (exclusive of depreciation and amortization) of 39% in Q4 2024 compared to 21% for the consolidated business Commerce Media Solutions annual revenue run rate currently exceeds $60 million, representing a 20% quarter-over-quarter increase, which demonstrates strong traction in executing a strategic pivot to a fast-growing marketNEW YORK, Feb. 28, 2025 (GLOBE NEWSWIRE) — Fluent, Inc. (NASDAQ: FLNT), a commerce media solutions company, today reported unaudited results for the fourth quarter and fiscal year ended December 31, 2024. These results are preliminary and subject to ongoing audit procedures. Donald...

— On track to report initial data from Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025 — — IND-enabling studies ongoing for PM577 for Wilson’s Disease; expect to file IND and/or CTA in 1H 2026 — — Additional high-value programs advancing through preclinical development — CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the full year ended December 31, 2024 and provided a business update. “Entering 2025 marks the next chapter for Prime Medicine as we look to share initial data for our most advanced product candidate, PM359, in chronic granulomatous disease, the only Prime Editor currently in clinical...